ATE260971T1
(de)
*
|
1992-04-01 |
2004-03-15 |
Univ Rockefeller |
Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
|
US20020085993A1
(en)
*
|
1992-11-25 |
2002-07-04 |
Ralph M. Steinman |
Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
|
US6300090B1
(en)
|
1994-07-29 |
2001-10-09 |
The Rockefeller University |
Methods of use of viral vectors to deliver antigen to dendritic cells
|
US5871728A
(en)
*
|
1995-03-31 |
1999-02-16 |
University Of Pittsburgh |
Method of regulating dendritic cell maturation
|
US20010012632A1
(en)
*
|
1995-03-31 |
2001-08-09 |
Muriel Moser |
Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
|
US20020182730A1
(en)
*
|
1995-07-26 |
2002-12-05 |
Micheal L. Gruenberg |
Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
|
US7150992B1
(en)
*
|
1995-10-04 |
2006-12-19 |
Innunex Corporation |
Methods of preparing dendritic cells with flt3-ligand and antigen
|
US6080409A
(en)
*
|
1995-12-28 |
2000-06-27 |
Dendreon Corporation |
Immunostimulatory method
|
US7659119B2
(en)
*
|
1996-02-12 |
2010-02-09 |
Argos Therapeutics, Inc. |
Method and compositions for obtaining mature dendritic cells
|
EP0808897A1
(de)
*
|
1996-05-21 |
1997-11-26 |
I.D.M. Immuno-Designed Molecules |
Antigenpräsentierende Zellen, ein Verfahren zur deren Herstellung und deren Verwendung als zelluläre Impfstoffen
|
NZ333607A
(en)
*
|
1996-07-10 |
2000-08-25 |
Immunex Corp |
Method of stimulating the immune system by transfecting dendritic cells
|
US6458585B1
(en)
|
1996-08-14 |
2002-10-01 |
Nexell Therapeutics Inc. |
Cytokine-free culture of dendritic cells
|
US6977073B1
(en)
|
1997-02-07 |
2005-12-20 |
Cem Cezayirli |
Method for stimulating an immune response
|
US6251665B1
(en)
|
1997-02-07 |
2001-06-26 |
Cem Cezayirli |
Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
|
US20040110283A1
(en)
*
|
1997-02-27 |
2004-06-10 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
|
US20050169898A1
(en)
*
|
1997-04-15 |
2005-08-04 |
Jianlin Gong |
Cell fusions and methods of making and using the same
|
AU744042B2
(en)
|
1997-04-15 |
2002-02-14 |
Dana-Farber Cancer Institute, Inc. |
Dendritic cell hybrids
|
WO1998053048A1
(en)
*
|
1997-05-21 |
1998-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
|
EP2058389B1
(de)
|
1997-10-27 |
2016-05-18 |
Rockefeller University |
Definiertes Reifungsmedium für dendritische Zellen enthaltend TNF-alpha, IL-1beta, IL-6
|
WO1999029732A2
(en)
|
1997-12-08 |
1999-06-17 |
Lexigen Pharmaceuticals Corporation |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
AU2872199A
(en)
*
|
1998-02-20 |
1999-09-06 |
Rockefeller University, The |
Apoptotic cell-mediated antigen presentation to dendritic cells
|
US20020034819A1
(en)
*
|
1998-02-23 |
2002-03-21 |
Alan K. Smith |
Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
|
WO1999050392A1
(en)
|
1998-03-31 |
1999-10-07 |
Geron Corporation |
Methods and compositions for eliciting an immune response to a telomerase antigen
|
US7402307B2
(en)
*
|
1998-03-31 |
2008-07-22 |
Geron Corporation |
Method for identifying and killing cancer cells
|
US6936249B1
(en)
*
|
1998-04-15 |
2005-08-30 |
Genencor International, Inc. |
Proteins producing an altered immunogenic response and methods of making and using the same
|
US6835550B1
(en)
*
|
1998-04-15 |
2004-12-28 |
Genencor International, Inc. |
Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
|
US20040202645A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Khan Nisar Ahmed |
Administration of gene-regulatory peptides
|
US20050227925A1
(en)
*
|
2004-04-08 |
2005-10-13 |
Robbert Benner |
Compositions capable of reducing elevated blood urea concentration
|
US8680059B2
(en)
*
|
1998-05-20 |
2014-03-25 |
Biotempt B.V. |
Oligopeptide acetate and formulations thereof
|
US6921751B1
(en)
*
|
1998-05-20 |
2005-07-26 |
Erasmus Universiteit Rotterdam |
Immunoregulator
|
EP1138692A1
(de)
*
|
2000-03-29 |
2001-10-04 |
Erasmus Universiteit Rotterdam |
Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
|
US20030220258A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Robbert Benner |
Treatment of ischemic events
|
US6844315B2
(en)
|
1998-05-20 |
2005-01-18 |
Erasmus Universiteit Rotterdam |
Immunoregulator
|
US20020051783A1
(en)
*
|
1998-06-05 |
2002-05-02 |
Savage Philip Michael |
Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
|
US7521197B2
(en)
*
|
1998-06-05 |
2009-04-21 |
Alexis Biotech Limited |
Method for producing cytotoxic T-cells
|
US7264965B2
(en)
*
|
1998-06-05 |
2007-09-04 |
Alexis Biotech Limited |
Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
|
US6558951B1
(en)
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
CA2367692A1
(en)
*
|
1999-03-15 |
2000-09-21 |
Introgen Therapeutics, Inc. |
Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
|
US20020090381A1
(en)
*
|
1999-04-09 |
2002-07-11 |
H. Kim Bottomly |
System for controlling immune system response to antigen
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
JP4637368B2
(ja)
|
1999-04-14 |
2011-02-23 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法
|
BR0010322A
(pt)
*
|
1999-05-06 |
2002-04-09 |
Univ Wake Forest |
Vetor de expressão, vacina e seu método de uso para eliciar uma resposta imune dirigida contra um antìgeno em um mamìfero
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7713739B1
(en)
|
2000-11-17 |
2010-05-11 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticle-based transfection and activation of dendritic cells
|
CN1235911C
(zh)
|
1999-08-09 |
2006-01-11 |
利思进药品公司 |
多细胞因子-抗体复合物
|
US7005131B1
(en)
|
1999-08-13 |
2006-02-28 |
The Rockefeller University |
Protective antigen of Epstein Barr Virus
|
DE60040672D1
(de)
|
1999-08-31 |
2008-12-11 |
Univ North Carolina |
Antikörper-abhängige vergrösserung der alphavirus-infektvität
|
PT1224264E
(pt)
|
1999-10-15 |
2010-03-15 |
Baylor Res Inst |
Modificação de células imunogénicas
|
US20030077263A1
(en)
*
|
1999-10-29 |
2003-04-24 |
Immunex Corporation |
Method of activating dendritic cells
|
EP1228214A2
(de)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietinformen mit verbesserten eigenschaften
|
US7030228B1
(en)
|
1999-11-15 |
2006-04-18 |
Miltenyi Biotec Gmbh |
Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
|
EP1259592A1
(de)
*
|
2000-01-11 |
2002-11-27 |
Maxygen, Inc. |
Monozyten abgeleitete dendritische zellen untegruppen
|
WO2001051500A1
(en)
*
|
2000-01-14 |
2001-07-19 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
DK1252192T3
(da)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
US6423539B2
(en)
|
2000-02-24 |
2002-07-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adjuvant treatment by in vivo activation of dendritic cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
WO2001062092A1
(en)
*
|
2000-02-25 |
2001-08-30 |
Thomas Jefferson University |
Formulations and methods for using the same to elicit an immune response
|
EP1300418A1
(de)
*
|
2001-10-04 |
2003-04-09 |
Erasmus Universiteit Rotterdam |
Genregulation durch Oligopeptide
|
US7358330B2
(en)
*
|
2001-03-29 |
2008-04-15 |
Biotempt B.V. |
Immunoregulatory compositions
|
US7361329B2
(en)
*
|
2000-04-21 |
2008-04-22 |
Chemocentryx, Inc. |
Compositions for inducing an immune response
|
AU5976001A
(en)
*
|
2000-05-12 |
2001-11-26 |
Northwest Biotherapeutics Inc |
Method to increase class i presentation of exogenous antigens by human dendriticcells
|
ES2288967T3
(es)
*
|
2000-06-29 |
2008-02-01 |
Merck Patent Gmbh |
Reforzamiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citoquina por medio del tratamiento combinado por agentes que mejoran la incorporacion de inmunocitoquina.
|
AU2524502A
(en)
*
|
2000-10-13 |
2002-04-22 |
Richard Boyd |
Improvement of graft acceptance through manipulation of thymic regeneration
|
US6892140B1
(en)
|
2000-11-27 |
2005-05-10 |
Enteron, Inc. |
Immunogenic cancer peptides and uses thereof
|
US20020094545A1
(en)
*
|
2000-11-30 |
2002-07-18 |
Harris Paul E. |
Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
|
US20030027334A1
(en)
*
|
2000-12-13 |
2003-02-06 |
Fitzpatrick David R. |
Method for generating immortal dendritic cell lines
|
EP1351969A4
(de)
*
|
2000-12-13 |
2006-04-05 |
Immunex Corp |
Verfahren zur erzeugung unsterblicher dendritischer zellinien
|
MXPA03008031A
(es)
|
2001-03-07 |
2003-12-04 |
Merck Patent Gmbh |
Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
|
FR2821947B1
(fr)
*
|
2001-03-12 |
2003-05-16 |
Canon Kk |
Procede et dispositif de validation de parametres definissant une image
|
US20020131953A1
(en)
*
|
2001-03-14 |
2002-09-19 |
Ut Southwestern Medical Center |
In situ langerhans cell vaccine
|
US20030165479A1
(en)
*
|
2001-03-19 |
2003-09-04 |
Velleca Mark A. |
Methods for isolating proteins expressed by dendritic cells
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
EP1373475A2
(de)
*
|
2001-04-02 |
2004-01-02 |
Alimentary Health Limited |
Auf dendritischen zellen basierende immuntherapie
|
US20020193295A1
(en)
*
|
2001-05-04 |
2002-12-19 |
Emanuel Calenoff |
Immunogenic peptides and uses thereof
|
KR20020083634A
(ko)
*
|
2001-04-27 |
2002-11-04 |
크레아젠 주식회사 |
수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
|
US20030082806A1
(en)
*
|
2001-04-27 |
2003-05-01 |
Xcyte Therapies, Inc. |
Maturation of antigen-presenting cells using activated T cells
|
US6969517B2
(en)
|
2001-05-03 |
2005-11-29 |
Emd Lexigen Research Center Corp. |
Recombinant tumor specific antibody and use thereof
|
AU2002326463A1
(en)
*
|
2001-07-25 |
2003-02-17 |
Northwest Biotherapeutics, Inc. |
Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
AU2002361468A1
(en)
|
2001-08-14 |
2003-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human S |
Method for rapid generation of mature dendritic cells
|
US20030134415A1
(en)
*
|
2001-09-19 |
2003-07-17 |
Gruenberg Micheal L. |
Th1 cell adoptive immunotherapy
|
US20030134341A1
(en)
*
|
2001-09-19 |
2003-07-17 |
Medcell Biologics, Llc. |
Th1 cell adoptive immunotherapy
|
US20030220259A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Robbert Benner |
Treatment of neurological disorders
|
US20030215460A1
(en)
*
|
2002-05-07 |
2003-11-20 |
Schall Thomas J. |
Methods and compositions for inducing an immune response
|
US20030096260A1
(en)
*
|
2001-10-09 |
2003-05-22 |
Zhenhua Miao |
Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
|
ES2381025T3
(es)
|
2001-12-04 |
2012-05-22 |
Merck Patent Gmbh |
Inmunocitocinas con selectividad modulada
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
US7615227B2
(en)
|
2001-12-20 |
2009-11-10 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce angiogenesis
|
US20030220260A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Khan Nisar Ahmed |
Peptide compositions
|
US20040013661A1
(en)
*
|
2001-12-21 |
2004-01-22 |
Gert Wensvoort |
Stratification
|
US7560433B2
(en)
*
|
2001-12-21 |
2009-07-14 |
Biotempt B.V. |
Treatment of multiple sclerosis (MS)
|
US20030220257A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Robbert Benner |
Treatment of trauma
|
US20080318871A1
(en)
*
|
2001-12-21 |
2008-12-25 |
Khan Nisar A |
Treatment of neurological disorders
|
US20080242837A1
(en)
*
|
2001-12-21 |
2008-10-02 |
Khan Nisar A |
Peptide compositions
|
US20030220261A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Khan Nisar Ahmed |
Treatment of iatrogenic disease
|
US20030224995A1
(en)
*
|
2001-12-21 |
2003-12-04 |
Khan Nisar Ahmed |
Treatment of burns
|
US7501391B2
(en)
*
|
2001-12-21 |
2009-03-10 |
Biotempt B.V. |
Treatment of transplant survival
|
US7786084B2
(en)
*
|
2001-12-21 |
2010-08-31 |
Biotempt B.V. |
Treatment of burns
|
US20030149646A1
(en)
*
|
2002-02-01 |
2003-08-07 |
Ubs Painewebber Inc. |
Method and system for providing an aggregated stock options report
|
US20030175272A1
(en)
*
|
2002-03-07 |
2003-09-18 |
Medcell Biologics, Inc. |
Re-activated T-cells for adoptive immunotherapy
|
US7060494B2
(en)
*
|
2002-04-09 |
2006-06-13 |
Reliance Life Sciences Pvt. Ltd. |
Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof
|
US7763251B2
(en)
*
|
2002-04-12 |
2010-07-27 |
Medical College Of Georgia Research Institute, Inc. |
Kits to assess the risk of tumor progression
|
ATE534035T1
(de)
*
|
2002-05-08 |
2011-12-15 |
Northwest Biotherapeutics Inc |
Qualitätstests für antigenpräsentierende zellen
|
US7048922B2
(en)
*
|
2002-05-29 |
2006-05-23 |
Demao Yang |
Stimulation of hematopoiesis by ex vivo activated immune cells
|
US7332158B2
(en)
*
|
2002-05-29 |
2008-02-19 |
Demao Yang |
Compositions and treatments for myelosuppression by ex vivo activated immune cells
|
CA2388441A1
(en)
*
|
2002-06-10 |
2003-12-10 |
Wei-Ping Min |
Immunomodulation using rna interference
|
AU2003267088A1
(en)
*
|
2002-09-11 |
2004-04-30 |
Medical College Of Georgia Research Institute, Inc. |
Chemokine receptor antagonists as therapeutic agents
|
US8263091B2
(en)
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
AU2003297557B2
(en)
|
2002-11-21 |
2009-02-26 |
Cellscript, Inc. |
Methods for using primers that encode one strand of a double-stranded promoter
|
ES2354944T3
(es)
|
2002-12-06 |
2011-03-21 |
Northwest Biotherapeutics, Inc. |
Administración de células dendríticas maduradas parcialmente in vitro para el tratamiento de tumores.
|
PT1572748E
(pt)
|
2002-12-17 |
2010-09-28 |
Merck Patent Gmbh |
Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
|
AU2004204942A1
(en)
*
|
2003-01-08 |
2004-07-29 |
Xencor, Inc |
Novel proteins with altered immunogenicity
|
EP1583423A4
(de)
*
|
2003-01-16 |
2006-05-10 |
Becton Dickinson Co |
Intradermale abgabe von zellen mittels dünner mikrokanüle
|
US20040197903A1
(en)
*
|
2003-01-31 |
2004-10-07 |
Northwest Biotherapeutics, Inc. |
Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15
|
EP1597356A4
(de)
*
|
2003-02-10 |
2007-07-11 |
Northwest Biotherapeutics Inc |
Antigenpräsentierende cd14+-kulturzellen
|
US20060134067A1
(en)
*
|
2003-02-18 |
2006-06-22 |
Maxcyte, Inc. |
Loading of cells with antigens by electroporation
|
RU2341289C2
(ru)
*
|
2003-02-21 |
2008-12-20 |
ХАСУМИ Эл-Эл-Си (Ди-Би-Эй ШУКОКАЙ ИНТЕРНЭШНЛ) |
Способ усиления иммунного ответа на антиген у млекопитающих
|
DK1604016T3
(da)
|
2003-02-27 |
2009-05-18 |
Northwest Biotherapeutics Inc |
In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler
|
US7323333B2
(en)
*
|
2003-03-31 |
2008-01-29 |
University Of South Florida |
Materials and methods for regulating process formation in cell culture
|
US20040203142A1
(en)
*
|
2003-04-14 |
2004-10-14 |
Reliance Life Sciences Pvt. Ltd. |
Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes
|
WO2005007839A1
(ja)
*
|
2003-07-22 |
2005-01-27 |
Kirin Beer Kabushiki Kaisha |
ノッチリガンドDelta-1、GM-CSF、TGF-βを用いたヒト末梢血単核球であるCD14陽性細胞からのランゲルハンス細胞の調製方法
|
EP1670513B1
(de)
*
|
2003-10-06 |
2013-01-23 |
Cedars-Sinai Medical Center |
Cox-2-inhibitoren und dendritische zellen zur verwendung in der krebsbehandlung
|
EP1676132B1
(de)
*
|
2003-10-21 |
2014-01-22 |
Cedars-Sinai Medical Center |
Kombination von Chemotherapie und Applikation von Glioma-Antigen-gepulsten dendritischen Zellen zur Glioma Behandlung
|
US20090227505A1
(en)
*
|
2004-01-07 |
2009-09-10 |
Biotempt B.V. |
Methods and uses for protein breakdown products
|
WO2005077412A2
(en)
*
|
2004-01-26 |
2005-08-25 |
Chemocentryx |
Compositions and methods of use of w-peptides
|
US20070087986A1
(en)
*
|
2004-01-26 |
2007-04-19 |
Brett Premack |
Compositions and methods for enhancing immunity by chemoattractant adjuvants
|
US20050214268A1
(en)
*
|
2004-03-25 |
2005-09-29 |
Cavanagh William A Iii |
Methods for treating tumors and cancerous tissues
|
DE602004023238D1
(de)
|
2004-05-11 |
2009-10-29 |
Shukokai Inc |
Methoden zur Kultivierung von Antigen presentierenden Immunzellen
|
EP1755626A4
(de)
*
|
2004-05-17 |
2008-10-01 |
Univ Illinois |
Verwendungen von bispezifischen antikörper (biab) beschichteten dendritischen zellen mit antigenen gepulst
|
AU2005327198B2
(en)
*
|
2004-07-09 |
2011-03-31 |
University Of North Carolina At Chapel Hill |
Viral adjuvants
|
CA2504451A1
(en)
*
|
2004-08-10 |
2006-02-10 |
Geron Corporation |
Dendritic cell vaccines for treating cancer made from embryonic stem cells
|
US20060057121A1
(en)
*
|
2004-09-10 |
2006-03-16 |
Demao Yang |
Compositions and treatments using ex vivo activated cells for myelosuppressed patients
|
CN101080487B
(zh)
|
2004-10-07 |
2012-11-14 |
阿戈斯治疗公司 |
成熟树突细胞组合物及其培养方法
|
DE602005025525D1
(de)
*
|
2004-11-17 |
2011-02-03 |
Amgen Inc |
Vollständige humane monoklonale antikörper gegen il-13
|
US20090028876A1
(en)
*
|
2005-01-24 |
2009-01-29 |
University Of Rochester |
Methods of modifying cd11c+ dendritic cell development to form osteoclasts functional in the bone environment
|
EP1856250B1
(de)
*
|
2005-02-15 |
2013-07-24 |
The University of North Carolina At Chapel Hill |
Neue lebende virus-impfstoffe
|
US20090263421A1
(en)
*
|
2005-05-10 |
2009-10-22 |
Anna-Lena Spetz-Holmgren |
Cellular vaccine
|
CN101291687A
(zh)
*
|
2005-05-12 |
2008-10-22 |
因特罗根治疗公司 |
用于癌症治疗的p53疫苗
|
AU2006266609C1
(en)
*
|
2005-07-05 |
2011-10-27 |
Biotempt B.V. |
Treatment of tumors
|
CN103589684A
(zh)
*
|
2005-12-08 |
2014-02-19 |
西北生物治疗药物公司 |
用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法
|
EP1864692A1
(de)
*
|
2006-06-07 |
2007-12-12 |
Biotempt B.V. |
Verwendung von peptiden zum Schutz von Strahlenschäden
|
US20100196336A1
(en)
|
2006-05-23 |
2010-08-05 |
Dongsu Park |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
CN101511384A
(zh)
|
2006-06-30 |
2009-08-19 |
贝勒研究院 |
采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞
|
US8129184B2
(en)
*
|
2006-09-26 |
2012-03-06 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
US8871211B2
(en)
|
2006-09-28 |
2014-10-28 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
GB0622399D0
(en)
*
|
2006-11-10 |
2006-12-20 |
Avaris Ab |
Novel compositions and uses thereof
|
US20080286315A1
(en)
*
|
2007-01-31 |
2008-11-20 |
Penta Biotech, Inc. |
Methionine Enkephalin as an Adjuvant for Vaccine Immunizations
|
DE102007006736B4
(de)
|
2007-02-07 |
2012-01-12 |
Dagmar Briechle |
In-vitro Testkit zur tierversuchsfreien Bestimmung des sensibilisierenden Potentials einer Substanz
|
KR100887560B1
(ko)
*
|
2007-04-24 |
2009-03-09 |
크레아젠 주식회사 |
준성숙 수지상 세포를 포함하는 류마티스 관절염 치료용약제학적 조성물
|
EP2173374A2
(de)
*
|
2007-07-24 |
2010-04-14 |
Stichting Katholieke Universiteit, Radboud University Nijmegen Medical Centre |
Zusammensetzungen und verfahren zur erzeugung einer immunantwort in einer person
|
US8513208B2
(en)
|
2008-02-28 |
2013-08-20 |
Argos Therapeutics, Inc. |
Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
|
DK2328923T3
(en)
*
|
2008-09-02 |
2016-03-21 |
Cedars Sinai Medical Center |
CD133 epitopes
|
WO2010129895A2
(en)
*
|
2009-05-07 |
2010-11-11 |
Immunocellular Therapeutics, Ltd. |
Cd133 epitopes
|
EP2281579A1
(de)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Impfstoffzusammensetzung mit 5'-Cap-modifizierter RNA
|
EP2678425B1
(de)
*
|
2011-02-23 |
2017-08-23 |
Kyoto University |
Verfahren zur herstellung dendritischer zellen aus pluripotenten stammzellen
|
CN109536446B
(zh)
*
|
2012-02-10 |
2022-08-02 |
医疗法人社团博心厚生会 |
单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法
|
US20140234351A1
(en)
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd. |
Cancer vaccines and vaccination methods
|
EP3071688B1
(de)
|
2013-11-18 |
2020-07-08 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Auf mikrokügelchen basierte freisetzung und ex-vivo-manipulation von dendritischen zellen für autoimmuntherapien
|
WO2015199402A1
(ko)
|
2014-06-23 |
2015-12-30 |
제이더블유크레아젠 주식회사 |
특정 유전자 발현이 증가된 수지상세포의 제조방법 및 이를 이용하여 제조된 수지상세포를 포함하는 자가면역질환 치료 또는 예방용 조성물
|
US10849985B2
(en)
|
2015-05-20 |
2020-12-01 |
Yeda Research And Development Co. Ltd. |
Method of targeting senescent cells
|
US20170216354A1
(en)
*
|
2015-06-12 |
2017-08-03 |
Batu Biologics, Inc. |
Clinically useful non-antigen pulsed dendritic cells
|
HUE059560T2
(hu)
|
2015-09-15 |
2022-11-28 |
Northwest Biotherapeutics Inc |
Elõrehaladott rákban szenvedõ alanyok részére való aktivált dendritikus sejtkészítményekkel kapcsolatos eljárások
|
EP3377635A4
(de)
|
2015-11-18 |
2019-05-08 |
Orbis Health Solutions LLC |
T7-alpha-virusvektorsystem
|
JP7185530B2
(ja)
|
2016-06-13 |
2022-12-07 |
トルク セラピューティクス, インコーポレイテッド |
免疫細胞機能を促進するための方法および組成物
|
US11364264B2
(en)
|
2016-09-09 |
2022-06-21 |
The General Hospital Corporation |
Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
WO2018213803A1
(en)
|
2017-05-19 |
2018-11-22 |
Neon Therapeutics, Inc. |
Immunogenic neoantigen identification
|
CN111432836A
(zh)
|
2017-09-05 |
2020-07-17 |
转矩医疗股份有限公司 |
治疗性蛋白质组合物及其制备和使用方法
|
CA3081840A1
(en)
|
2017-11-08 |
2019-05-16 |
Neon Therapeutics, Inc. |
T cell manufacturing compositions and methods
|
CN112243382A
(zh)
|
2018-01-18 |
2021-01-19 |
南佛罗里达大学 |
死抗原刺激的未成熟异源性树突细胞作为疾病治疗剂
|